The medical technology industry has garnered significant interest from investors lately, and Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a company that stands out for potential tracking. Engaged in offering rapid, non-invasive, and smart testing solutions, it could be worth keeping an eye on.
On December 19, 2023, the company made headlines by revealing its achievement of accreditation from the National Association of Testing Authorities (NATA) for its Intelligent Fingerprinting Drug Screening System. This significant milestone marked a noteworthy advancement for Intelligent Bio Solutions, gaining recognition and acknowledgment not only in the United States but also internationally.
It would offer a means of acknowledging the competencies of organizations accredited in specialized scientific and technical domains. NATA accreditation is granted following a comprehensive process aligned with ISO standards. A panel of experts thoroughly reviews the application before accrediting an organization.
Harry Simeonidis, the Chief Executive Officer and President of Intelligent Bio Solutions, also addressed this milestone. He emphasized that gaining NATA accreditation was a 'significant achievement' for the company. Simeonidis praised the dedication and determination of Intelligent Bio Solutions' team in reaching this goal. He expressed that the NATA accreditation would broaden opportunities in both the national and international markets for Intelligent Bio Solutions.
Furthermore, he added that the recognition underscored Intelligent Bio Solutions' dedication to the utmost standards in delivering and advancing its flagship product, the Intelligent Fingerprinting Drug Screening System. In the press release, the company emphasized that the accreditation would act as an autonomous benchmark for technical excellence, showcasing Intelligent Bio Solutions' commitment to safety, quality, and reliability.
In December 2023, Intelligent Bio Solutions Inc. (NASDAQ: INBS) achieved a significant closing peak at $0.438, reaching an intraday high of $0.529. Presently, the stock is in oversold conditions, trading at $0.319 with a 5-day change showing an increase of 3.02%, indicating a potential recovery and a resumption of an upward trajectory. This positions it as a stock worthy of close observation in the current period and the coming weeks.
Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content."TSR" is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. "TSR" authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. "TSR" has not been compensated to produce content related to "Any Companies" appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.
Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email: Send Email
Country: United States
Website: http://www.thestreetreports.com
